Lactobacillus acidophilus K301 Inhibits Atherogenesis via Induction of 24 (S), 25-Epoxycholesterol-Mediated ABCA1 and ABCG1 Production and Cholesterol Efflux in Macrophages

Hong, Yifan; Kim, Hangeun; Kim, Hye Sun; Park, Woo Jung; Kim, Joo-Yun; Chung, Dae Kyun

doi:10.1371/journal.pone.0154302

Cited by 21 publications

(15 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TG has now been recognized as a strong marker for CVD and diabetes, as well as NAFLD [4]. Probiotics have been reported to exert their lipid-modulating effect by regulating the host genes responsible for lipid metabolism [20,24,25]. In this study, it was observed that L. plantarum DR7 and L. fermentum DR9 significantly downregulated the gene expression of SCD1 in the liver, where the former showed a more prominent effect.…”

Section: Discussionmentioning

confidence: 56%

Lactobacillus Strains Alleviated Hyperlipidemia and Liver Steatosis in Aging Rats via Activation of AMPK

Lew

Hor

Jaafar

et al. 2020

IJMS

View full text Add to dashboard Cite

In this study, we hypothesized that different strains of Lactobacillus can alleviate hyperlipidemia and liver steatosis via activation of 5′ adenosine monophosphate-activated protein kinase (AMPK), an enzyme that is involved in cellular energy homeostasis, in aged rats. Male rats were fed with a high-fat diet (HFD) and injected with D-galactose daily over 12 weeks to induce aging. Treatments included (n = 6) (i) normal diet (ND), (ii) HFD, (iii) HFD-statin (lovastatin 2 mg/kg/day), (iv) HFD-Lactobacillus fermentum DR9 (10 log CFU/day), (v) HFD-Lactobacillus plantarum DR7 (10 log CFU/day), and (vi) HFD-Lactobacillus reuteri 8513d (10 log CFU/day). Rats administered with statin, DR9, and 8513d reduced serum total cholesterol levels after eight weeks (p < 0.05), while the administration of DR7 reduced serum triglycerides level after 12 weeks (p < 0.05) as compared to the HFD control. A more prominent effect was observed from the administration of DR7, where positive effects were observed, ranging from hepatic gene expressions to liver histology as compared to the control (p < 0.05); downregulation of hepatic lipid synthesis and β-oxidation gene stearoyl-CoA desaturase 1 (SCD1), upregulation of hepatic sterol excretion genes of ATP-binding cassette subfamily G member 5 and 8 (ABCG5 and ABCG8), lesser degree of liver steatosis, and upregulation of hepatic energy metabolisms genes AMPKα1 and AMPKα2. Taken altogether, this study illustrated that the administration of selected Lactobacillus strains led to improved lipid profiles via activation of energy and lipid metabolisms, suggesting the potentials of Lactobacillus as a promising natural intervention for alleviation of cardiovascular and liver diseases.

show abstract

Section: Discussionmentioning

confidence: 56%

Lactobacillus Strains Alleviated Hyperlipidemia and Liver Steatosis in Aging Rats via Activation of AMPK

Lew

Hor

Jaafar

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…The differentiation of THP-1 to macrophages was confirmed by increasing CD36 and decreasing CCR2 (Fig. 1C) [14]. In addition, cell viability was not affected by the ligands used in this study (Fig.…”

Section: Optimization Of Anti-inflammatory Status For In Vitro Studysupporting

confidence: 51%

Lipoteichoic Acid Isolated from Lactobacillus plantarum Maintains Inflammatory Homeostasis through Regulation of Th1- and Th2- Induced Cytokines

Ahn¹,

Kim²,

Chung³

2019

Journal of Microbiology and Biotechnology

Self Cite

View full text Add to dashboard Cite

Lipoteichoic acid isolated from Lactobacillus plantarum K8 (pLTA) alleviates lipopolysaccharide (LPS)-induced excessive inflammation through inhibition of TNF-α and interleukin (IL)-6. In addition, pLTA increases the survival rate of mice in a septic shock model. In the current study, we have found that pLTA contributes to homeostasis through regulation of pro-and anti-inflammatory cytokine production. In detail, pLTA decreased the production of IL-10 by phorbol-12-myristate-13-acetate (PMA)-differentiated THP-1 cells stimulated with prostaglandin E2 (PGE-2) and LPS. However, TNF-α production which was inhibited by PGE-2+LPS increased by pLTA treatment. The regulatory effects of IL-10 and TNF-α induced by PGE-2 and LPS in PMA-differentiated THP-1 cells were mediated by pLTA, but not by other LTAs isolated from either Staphylococcus aureus (aLTA) or L. sakei (sLTA). Further studies revealed that pLTA-mediated IL-10 inhibition and TNF-α induction in PGE-2+LPS-stimulated PMAdifferentiated THP-1 cells were mediated by dephosphorylation of p38 and phosphorylation of c-Jun N-terminal kinase (JNK), respectively. Reduction of pLTA-mediated IL-10 inhibited the metastasis of breast cancer cells (MDA-MB-231), which was induced by IL-10 or conditioned media prepared from PGE-2+LPS-stimulated PMA-differentiated THP-1 cells. Taken together, our data suggest that pLTA contributes to inflammatory homeostasis through induction of repressed pro-inflammatory cytokines as well as inhibition of excessive antiinflammatory cytokines.

show abstract

“…For example, meta-analysis of 15 studies with 788 subjects showed effective lowering of cardiovascular risk factors such as total cholesterol, LDL-C and inflammatory markers [ 107 ], conclusions that are supported by another similar meta-analysis [ 108 ]. Studies in mouse model systems have also shown attenuation of atherosclerosis by probiotic bacteria via multiple mechanisms, including induction of tolerogenic dendritic cells [ 109 ], stimulation of cholesterol efflux [ 110 ] and reduction in both intestinal cholesterol uptake and vascular inflammation [ 111 , 112 ].…”

Section: Dietary Fiber Gut Microbiota Prebiotics and Probioticsmentioning

confidence: 99%

Nutraceuticals as therapeutic agents for atherosclerosis

Moss

Williams

Ramji

2018

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Diseas

116

View full text Add to dashboard Cite

Atherosclerosis, a chronic inflammatory disorder of medium and large arteries and an underlying cause of cardiovascular disease (CVD), is responsible for a third of all global deaths. Current treatments for CVD, such as optimized statin therapy, are associated with considerable residual risk and several side effects in some patients. The outcome of research on the identification of alternative pharmaceutical agents for the treatment of CVD has been relatively disappointing with many promising leads failing at the clinical level. Nutraceuticals, products from food sources with health benefits beyond their nutritional value, represent promising agents in the prevention of CVD or as an add-on therapy with current treatments. This review will highlight the potential of several nutraceuticals, including polyunsaturated fatty acids, flavonoids and other polyphenols, as anti-CVD therapies based on clinical and pre-clinical mechanism-based studies.

show abstract

Lactobacillus acidophilus K301 Inhibits Atherogenesis via Induction of 24 (S), 25-Epoxycholesterol-Mediated ABCA1 and ABCG1 Production and Cholesterol Efflux in Macrophages

Cited by 21 publications

References 36 publications

Lactobacillus Strains Alleviated Hyperlipidemia and Liver Steatosis in Aging Rats via Activation of AMPK

Lactobacillus Strains Alleviated Hyperlipidemia and Liver Steatosis in Aging Rats via Activation of AMPK

Lipoteichoic Acid Isolated from Lactobacillus plantarum Maintains Inflammatory Homeostasis through Regulation of Th1- and Th2- Induced Cytokines

Nutraceuticals as therapeutic agents for atherosclerosis

Contact Info

Product

Resources

About